NCT07668037 Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy
| NCT ID | NCT07668037 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| Condition | Non-Small Cell Carcinoma of Lung |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2026-05-01 |
| Primary Completion | 2030-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2026-05-01 with a primary completion date of 2030-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a retrospective, multicenter, observational cohort study in patients with advanced or locally advanced non-small cell lung cancer (NSCLC). The aim of this study was to establish a long-term survival (LTS) versus short-term survival (STS) real-world cohort, to systematically characterize the multi-omics landscapes, and to develop and validate an artificial intelligence (AI) pathological prediction model based on routine H\&E-stained images for predicting immune microenvironment features and long-term survival outcomes following immunotherapy.
Eligibility Criteria
Inclusion Criteria: * Patients with pathologically confirmed advanced or locally advanced non-small cell lung cancer (NSCLC). * Patients derived from real-world data of multiple centers (including Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital of Shanxi, Chinese Academy of Medical Sciences \[Shanxi Cancer Hospital\]; and other participating centers) or from completed phase III clinical trials (e.g., Choice-01, Rationale-307, Rationale-304). * Patients who received first-line or later-line immune checkpoint inhibitor (ICI) monotherapy or ICI-based combination therapy. * Patients with complete clinical information and available follow-up data. Exclusion Criteria: * Patients whose systemic therapy did not include an immunotherapy regimen. * Patients lost to follow-up.
Contact & Investigator
Jie Wang, MD, PhD
PRINCIPAL INVESTIGATOR
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Frequently Asked Questions
Who can join the NCT07668037 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non-Small Cell Carcinoma of Lung. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07668037 currently recruiting?
Yes, NCT07668037 is actively recruiting participants. Contact the research team at zlhuxi@163.com for enrollment information.
Where is the NCT07668037 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07668037 clinical trial?
NCT07668037 is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. The principal investigator is Jie Wang, MD, PhD at Cancer Institute and Hospital, Chinese Academy of Medical Sciences. The trial plans to enroll 600 participants.